FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313646767> ?p ?o ?g. }

• W4313646767 endingPage "22" @default.
• W4313646767 startingPage "22" @default.
• W4313646767 abstract "(1) Background: Currently, echocardiography is the primary non-invasive diagnostic method used to screen patients with severe aortic valve stenosis (AS) for pulmonary hypertension (PH) by estimating systolic pulmonary artery pressure (sPAP). Other radiological methods have been a focus of research in the past couple of years, as it was shown that by determining the pulmonary artery (PA) diameter, prognostic statements concerning overall mortality could be made in these patients. This study compared established and novel cardiovascular biomarkers with the PA/BSA value to detect PH in patients with severe AS. (2) Methods: The study cohort comprised 188 patients with severe AS undergoing transcatheter aortic valve replacement (TAVR), who were then divided into two groups based on PA/BSA values obtained through CT-angiography. The presence of PH was defined as a PA/BSA ≥ 16.6 mm/m2 (n = 81), and absence as a PA/BSA < 16.6 mm/m2 (n = 107). Blood samples were taken before TAVR to assess cardiovascular biomarkers used in this study, namely brain natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitive troponin (hsTN), soluble suppression of tumorigenesis-2 (sST2), growth/differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), insulin-like growth factor binding protein 2 (IGF-BP2), and soluble urokinase-type plasminogen activator receptor (suPAR). (3) Results: Patients with a PA/BSA ≥ 16.6 mm/m2 showed significantly higher levels of BNP (p = <0.001), GDF-15 (p = 0.040), and H-FABP (p = 0.007). The other investigated cardiovascular biomarkers did not significantly differ between the two groups. To predict a PA/BSA ≥ 16.6 mm/m2, cut-off values for the biomarkers were calculated. Here, GDF-15 (p = 0.029; cut-off 1172.0 pg/mL) and BNP (p < 0.001; cut-off 2194.0 pg/mL) showed significant results. Consequently, analyses of combined biomarkers were performed, which yielded IGF-BP2 + BNP (AUC = 0.721; 95%CI = 0.585−0.857; p = 0.004) as the best result of the two-way analyses and GDF-15 + IGF-BP2 + BNP (AUC = 0.727; 95%CI = 0.590−0.864; p = 0.004) as the best result of the three-way analyses. No significant difference regarding the 1-year survival between patients with PA/BSA < 16.6 mm/m2 and patients with PA/BSA ≥ 16.6 mm/m2 was found (log-rank test: p = 0.452). (4) Conclusions: Although PA/BSA aims to reduce the bias of the PA value caused by different body compositions and sizes, it is still a controversial parameter for diagnosing PH. Combining the parameter with different cardiovascular biomarkers did not lead to a significant increase in the diagnostic precision for detecting PH in patients with severe AS." @default.
• W4313646767 created "2023-01-07" @default.
• W4313646767 creator A5004744922 @default.
• W4313646767 creator A5005718914 @default.
• W4313646767 creator A5006082025 @default.
• W4313646767 creator A5016430407 @default.
• W4313646767 creator A5021590363 @default.
• W4313646767 creator A5030383675 @default.
• W4313646767 creator A5040800792 @default.
• W4313646767 creator A5046395462 @default.
• W4313646767 creator A5048183177 @default.
• W4313646767 creator A5053503784 @default.
• W4313646767 creator A5057164548 @default.
• W4313646767 creator A5058252352 @default.
• W4313646767 creator A5072768076 @default.
• W4313646767 creator A5075605495 @default.
• W4313646767 date "2023-01-05" @default.
• W4313646767 modified "2023-10-12" @default.
• W4313646767 title "A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis—The Rise of IGF-BP2 and GDF-15" @default.
• W4313646767 cites W1988710786 @default.
• W4313646767 cites W2008576197 @default.
• W4313646767 cites W2045610117 @default.
• W4313646767 cites W2065337622 @default.
• W4313646767 cites W2123946399 @default.
• W4313646767 cites W2407431736 @default.
• W4313646767 cites W2529388047 @default.
• W4313646767 cites W2617072789 @default.
• W4313646767 cites W2736135064 @default.
• W4313646767 cites W2773649379 @default.
• W4313646767 cites W2783363855 @default.
• W4313646767 cites W2800070433 @default.
• W4313646767 cites W2803218851 @default.
• W4313646767 cites W2804535766 @default.
• W4313646767 cites W2885012996 @default.
• W4313646767 cites W2888731088 @default.
• W4313646767 cites W2890022558 @default.
• W4313646767 cites W2892454581 @default.
• W4313646767 cites W2910283496 @default.
• W4313646767 cites W2939756343 @default.
• W4313646767 cites W2942342254 @default.
• W4313646767 cites W2955289247 @default.
• W4313646767 cites W2981667952 @default.
• W4313646767 cites W2999455111 @default.
• W4313646767 cites W3003438227 @default.
• W4313646767 cites W3006210704 @default.
• W4313646767 cites W3086619814 @default.
• W4313646767 cites W3126952118 @default.
• W4313646767 cites W3138847096 @default.
• W4313646767 cites W3153950084 @default.
• W4313646767 cites W4200341501 @default.
• W4313646767 cites W4221038324 @default.
• W4313646767 cites W4283453641 @default.
• W4313646767 cites W4285098294 @default.
• W4313646767 cites W4293217384 @default.
• W4313646767 doi "https://doi.org/10.3390/jcdd10010022" @default.
• W4313646767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36661917" @default.
• W4313646767 hasPublicationYear "2023" @default.
• W4313646767 type Work @default.
• W4313646767 citedByCount "0" @default.
• W4313646767 crossrefType "journal-article" @default.
• W4313646767 hasAuthorship W4313646767A5004744922 @default.
• W4313646767 hasAuthorship W4313646767A5005718914 @default.
• W4313646767 hasAuthorship W4313646767A5006082025 @default.
• W4313646767 hasAuthorship W4313646767A5016430407 @default.
• W4313646767 hasAuthorship W4313646767A5021590363 @default.
• W4313646767 hasAuthorship W4313646767A5030383675 @default.
• W4313646767 hasAuthorship W4313646767A5040800792 @default.
• W4313646767 hasAuthorship W4313646767A5046395462 @default.
• W4313646767 hasAuthorship W4313646767A5048183177 @default.
• W4313646767 hasAuthorship W4313646767A5053503784 @default.
• W4313646767 hasAuthorship W4313646767A5057164548 @default.
• W4313646767 hasAuthorship W4313646767A5058252352 @default.
• W4313646767 hasAuthorship W4313646767A5072768076 @default.
• W4313646767 hasAuthorship W4313646767A5075605495 @default.
• W4313646767 hasBestOaLocation W43136467671 @default.
• W4313646767 hasConcept C115725540 @default.
• W4313646767 hasConcept C126322002 @default.
• W4313646767 hasConcept C136935669 @default.
• W4313646767 hasConcept C164705383 @default.
• W4313646767 hasConcept C2775915353 @default.
• W4313646767 hasConcept C2778198053 @default.
• W4313646767 hasConcept C2780007028 @default.
• W4313646767 hasConcept C2780930700 @default.
• W4313646767 hasConcept C2780940725 @default.
• W4313646767 hasConcept C500558357 @default.
• W4313646767 hasConcept C71924100 @default.
• W4313646767 hasConceptScore W4313646767C115725540 @default.
• W4313646767 hasConceptScore W4313646767C126322002 @default.
• W4313646767 hasConceptScore W4313646767C136935669 @default.
• W4313646767 hasConceptScore W4313646767C164705383 @default.
• W4313646767 hasConceptScore W4313646767C2775915353 @default.
• W4313646767 hasConceptScore W4313646767C2778198053 @default.
• W4313646767 hasConceptScore W4313646767C2780007028 @default.
• W4313646767 hasConceptScore W4313646767C2780930700 @default.
• W4313646767 hasConceptScore W4313646767C2780940725 @default.
• W4313646767 hasConceptScore W4313646767C500558357 @default.
• W4313646767 hasConceptScore W4313646767C71924100 @default.
• W4313646767 hasIssue "1" @default.

• next